Affiliation: Wakayama Medical University
Imanishi T, Akasaka T. Biomarkers associated with vulnerable atheromatous plaque. Curr Med Chem. 2012;19:2588-96 pubmed
..Furthermore, assays for automated use need to be developed, and cut-off levels need to be defined. Further technological advances will likely facilitate the use of multimarker profiling to identify with coronary vulnerable plaque. ..
Imanishi T, Akasaka T. Novel strategies to target inflammatory processes in atherosclerosis. Curr Pharm Des. 2013;19:1616-25 pubmed
..Here, the impact of monocytes/macrophages in both early atherogenesis and advanced plaque progression is discussed with a focus on the potential targeting of inflammatory processes in atherosclerosis. ..
Imanishi T, Akasaka T. MicroRNAs in peripheral artery disease. Curr Top Med Chem. 2013;13:1589-95 pubmed
..Recent evidence has demonstrated that specific miRNAs are involved in the pathological development of PAD. In this review, the roles of specific miRNAs in PAD are summarized. ..
Imanishi T, Moriwaki C, Hano T, Nishio I. Endothelial progenitor cell senescence is accelerated in both experimental hypertensive rats and patients with essential hypertension. J Hypertens. 2005;23:1831-7 pubmed
..The hypertension-induced EPC senescence may affect the process of vascular remodeling. ..
Imanishi T, Kobayashi K, Kuroi A, Mochizuki S, Goto M, Yoshida K, et al
. Effects of angiotensin II on NO bioavailability evaluated using a catheter-type NO sensor. Hypertension. 2006;48:1058-65 pubmed
..Although Ang II stimulates release of NO in the short term, chronic treatment with Ang II elicits the decreased NO bioavailability in the aorta of the Ang II-infusion rabbit model. ..
Imanishi T, Kuroi A, Ikejima H, Kobayashi K, Muragaki Y, Mochizuki S, et al
. Effects of angiotensin converting enzyme inhibitor and angiotensin II receptor antagonist combination on nitric oxide bioavailability and atherosclerotic change in Watanabe heritable hyperlipidemic rabbits. Hypertens Res. 2008;31:575-84 pubmed publisher
..01). In conclusion, the combined treatment with an ACEI and an ARB may have additive protective effects on endothelial function as well as atherosclerotic change. ..
Imanishi T, Kobayashi K, Kuroi A, Ikejima H, Akasaka T. Pioglitazone inhibits angiotensin II-induced senescence of endothelial progenitor cell. Hypertens Res. 2008;31:757-65 pubmed publisher
..In conclusion, pioglitazone inhibited Ang II-induced senescence of EPCs via down-regulation of the expression of AT1R. ..
Ozaki Y, Imanishi T, Akasaka T. Inflammatory Biomarkers in Peripheral Artery Disease: Diagnosis, Prognosis, and Therapeutic Challenges. Curr Med Chem. 2015;22:2744-53 pubmed
..In this review, inflammatory biomarkers that should be contributory to diagnosis, prognosis, and avenues for therapeutic challenges in PAD are summarized. ..
Imanishi T, Ikejima H, Tsujioka H, Kuroi A, Kobayashi K, Muragaki Y, et al
. Addition of eplerenone to an angiotensin-converting enzyme inhibitor effectively improves nitric oxide bioavailability. Hypertension. 2008;51:734-41 pubmed publisher
..Combined treatment with a selective aldosterone antagonist and an angiotensin-converting enzyme inhibitor has additive protective effects on endothelial function and on atherosclerotic changes via decreased nitrosative stress. ..